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Financial cost of lymphedema borne by women with breast cancer
Abstract
Psycho-Oncology Published by John Wiley & Sons Ltd.Objective: Our study examines the financial cost of
lymphedema following a diagnosis of breast cancer and addresses a significant knowledge gap regarding the
additional impact of lymphedema on breast cancer survivors. Methods: An online national survey was
conducted with 361 women who had either breast cancer without lymphedema (BC) (group 1, n = 209) or
breast cancer with lymphedema (BC+LE) (group 2, n = 152). Participant recruitment was supported by the
Breast Cancer Network Australia and the Australasian Lymphology Association. Results: Both breast cancer
and lymphedema result in significant out-of-pocket financial costs borne by women. Of patients with BC+LE,
80% indicated that their breast cancer diagnosis had affected them financially compared with 67% in the BC
group (P < .020). For patients with lymphedema, over half (56%) indicated that this specific additional
diagnosis to their breast cancer affected them financially and that costs increased with lymphedema severity.
The cost of compression garments formed a large proportion of these costs (40.1%). The average number of
attendances to a therapist each year was 5.8 (range, 0-45). Twenty-five patients (16.4%) had an episode of
cellulitis in the past year. The incidence of cellulitis was 7.7% in 91 patients with subclinical or mild
lymphedema compared with 29.5% of 61 patients with more extensive lymphedema (P < .001). The average
out-of-pocket financial cost of lymphedema care borne by women was A$977 per annum, ranging from
A$207 for subclinical lymphedema to over A$1400 for moderate or severe lymphedema. Conclusions: This
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Objective Our study examines the financial cost of lymphedema following a diagnosis of
breast cancer and addresses a significant knowledge gap regarding the additional impact of
lymphedema on breast cancer survivors.
Methods An online national survey was conducted with 361 women who had either breast
cancer without lymphedema (BC) (group 1, n = 209) or breast cancer with lymphedema (BC+LE)
(group 2, n = 152). Participant recruitment was supported by the Breast Cancer Network
Australia and the Australasian Lymphology Association.
Results Both breast cancer and lymphedema result in significant out‐of‐pocket financial costs
borne by women. Of patients with BC+LE, 80% indicated that their breast cancer diagnosis had
affected them financially compared with 67% in the BC group (P < .020). For patients with
lymphedema, over half (56%) indicated that this specific additional diagnosis to their breast
cancer affected them financially and that costs increased with lymphedema severity. The cost
of compression garments formed a large proportion of these costs (40.1%). The average number
of attendances to a therapist each year was 5.8 (range, 0‐45). Twenty‐five patients (16.4%) had
an episode of cellulitis in the past year. The incidence of cellulitis was 7.7% in 91 patients with
subclinical or mild lymphedema compared with 29.5% of 61 patients with more extensive
lymphedema (P < .001). The average out‐of‐pocket financial cost of lymphedema care borne
by women was A$977 per annum, ranging from A$207 for subclinical lymphedema to over
A$1400 for moderate or severe lymphedema.
Conclusions This study identifies an additional detrimental effect of lymphedema on women
in terms of financial costs.
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1 | INTRODUCTION
As the number of breast cancer survivors increases with more effective
treatments, the number of patients with long‐term side effects
including lymphedema also increases.1 Surgery and/or radiation
therapy disrupts the lymphatics and thus increases the risk of fluid
accumulation.2,3 The incidence of breast cancer–related lymphedema
(BCRL) ranges from 5% with conservative treatment alone
(lumpectomy or wide local excision and sentinel node biopsy) to
greater than 50% in cases with axillary node dissections and nodal
irradiation.4–8 Patients who are obese or develop postoperative
seroma or infection are at added risk.9
Lymphedema not only causes pain and limits a patient's activities of
daily living but also directly impacts the financial costs to the individual
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through copayments for increased medical and therapist consultations
and the direct costs of compression garments and other treatment‐
related medical expenses.10 Lymphedema also increases the impact on
employment and career, which can also affect finances. For example,
patients may need to have more time off work or transition from full‐
time to part‐time employment to increase the time available to manage
the complex care required, particularly with advanced lymphedema.11
However, research into lymphedema is still limited, regarding not
only diagnosis and treatment but also the impact on a patient's quality
of life and costs to the economy. In a recent systematic analysis by the
International Lymphoedema Framework, Stout12,13 argued that
implementation of care models for lymphedema faced several barriers,
including the lack of population‐based prevalence studies, and specifi-
cally highlighted the lack of information on the economic burden of the
disease as data regarding lymphedema cost management and related
complications are limited.
Post‐treatment survivors of cancer face practical concerns relating
to financial costs. Patients with BCRL have higher treatment costs: for
example, compression therapy, the most crucial element in the
management of chronic lymphedema, involves wearing compression
garments on the affected limb. While ready‐to‐wear compression
garments cost A$130 to $250, customized garments deliver
significantly better results but cost approximately A$300 to A$500.
Patients require a minimum of 2 garments at a time to allow for
washing, and these require replacement every 6 months. In many
countries, including Australia, there is little government support for
lymphedema, and private health insurance reimbursement depends on
the patient's level of cover. In addition, patients with lymphedema are
more likely to spend more time in hospital owing to lymphangitis or cel-
lulitis, known to contribute to a more advanced condition and compound
medical costs.14
Scholars are beginning to examine these financial costs. Shih
et al15 found that the 2‐year mean costs for women with BCRL were
a significant US$23 167 higher than for patients with breast cancer
without lymphedema (BC). In a recent study of 56 075 women, 2.3%
had at least 1 hospital admission for complicated lymphedema within
2 years of breast cancer surgery.16 Along with significantly more
inpatient admissions, patients with BCRL incurred nearly 7‐fold greater
health care charges compared with those patients without lymph-
edema. This high rate of hospitalization resulted in substantially higher
health care charges (US$58 088 vs US$31 819 per patient, P < .001)
over the 2‐year period after surgery. However, studies of this type
are constrained because of the use of administrative claims data, which
are likely to underestimate true incidence rates and costs.13 With this
in mind, we undertook a mixed‐method qualitative and cross‐sectional
quantitative study to begin to further understand the impact of lymph-
edema over and above breast cancer in this important dimension.
2 | METHOD
2.1 | Setting
A survey of breast cancer survivors with and without lymphedema was
undertaken Australia‐wide. Participants were asked to complete an
electronic survey examining the impact of lymphedema over and
above breast cancer on their employment, social life, self‐esteem, body
image, and finances. This report specifically addresses the impact of
lymphedema over and above breast cancer on the financial costs borne
by women.
2.2 | Study population
Owing to limited knowledge about the socioeconomic impact of
lymphedema, an exploratory qualitative methods approach was used
that entailed interviews with 30 individuals—10 with primary lymph-
edema and 20 with secondary lymphedema. During the second phase,
reported here, we used survey methodology to collect extensive data
on the impact that living with secondary lymphedema has on breast
cancer survivors. The survey instrument is available on request. A
complexity addressed in the study was how to differentiate the
impact of a diagnosis of lymphedema over and above a diagnosis of
breast cancer. The survey instrument therefore had 2 sections looking
at the impact of lymphedema first (if present) and then breast cancer
for all patients.
Individuals eligible for study participation were as follows: female;
older than 18 years; previously diagnosed with primary stage I, II, or III
breast cancer; had completed treatment at least 1 year prior to
recruitment; and fluent in English. Individuals who fulfilled these
criteria alone became the control group. In addition, we targeted indi-
viduals who fulfilled all the criteria above and also had a confirmed
diagnosis of lymphedema, by either a doctor or lymphedema therapist,
including patients with subclinical lymphedema diagnosed through
bioimpedance spectroscopy (L‐Dex) alone; had sought therapist
advice; and/or were wearing compression garments. Participants com-
pleted the study questionnaire online.
Women previously diagnosed with breast cancer were
approached for study participation through an Australian commu-
nity–based breast cancer consumer organization, the Breast Cancer
Network Australia (BCNA). An e‐mail invitation was sent by a contact
person within the BCNA to members who had previously agreed to
receive notifications about research studies. Patients with lymph-
edema were also asked to consider the study through the Australasian
Lymphology Association (ALA) and through notices in the clinics of the
authors (J.B., L.K., and H.M.). Contact was made with an estimated
1600 patients with BC and 700 with breast cancer with lymphedema
(BC+LE), and it was the responsibility of the women who received
the e‐mail to determine their eligibility for the study. A total of 361
women agreed to participate. Following online consent, participants
anonymously completed the 30‐minute questionnaire. The survey
contained questions relating to the impact lymphedema had on family,
social/leisure activities, and employment, as well as self‐esteem and
identity. The conduct of this research was approved by the Macquarie
University Human Research Ethics Committee.
2.3 | Definitions
We asked a screening question so as to classify our respondents'
lymphedema stage (Sheila Ridner, personal communication). We asked
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participants to reflect on their condition for the last month and report
on its severity by choosing one of the following categories.
• No problem: no noticeable swelling. We later termed this category
as subclinical lymphedema detected by a therapist or clinician
using girth measures or bioimpedance spectroscopy (L‐Dex®).
• Mild lymphedema: soft swelling that is not obvious to others and
comes and goes.
• Moderate lymphedema: swelling with occasional hardness in some
areas that is obvious to others and is always present.
• Severe lymphedema: profuse swelling with thickened skin,
constant hardness, and a very large, heavy arm that is extremely
obvious to others and is always present.
2.4 | Data collection and statistical analysis
Patients with breast cancer were asked specific questions about how
their cancer affected the following domains: (1) employment/career;
(2) family life; (3) social/leisure; (4) self‐image; and (5) feeling about self.
For patients given a diagnosis of lymphedema, information about the
impact of lymphedema on employment, cost of seeing therapists, and
cost of compression sleeves was collected in addition to the above
domains. Data were collected between November 2014 and March
2015 using Qualtrics® survey software. Participants were directly
asked about the costs of managing lymphedema reported in Australian
dollars (A$). All P values are 2 sided using the statistical tests for
differences as specified.
3 | RESULTS
Of 361 patients, 209 (58%) had BC only and 152 (42%) had adiagnosis
of BC+LE. The severity of lymphedema was “not noticeable” in 14
(9%), mild in 77 (51%), moderate in 55 (36%), and severe in 6 patients
(4%). The time since onset of lymphedema was <5 years in 65% of
cases. Demographic features of the study participants are shown in
Table 1. Of note, total household income at the time of the survey
was $100 000 or more in about one‐third of patients (P = NS).
When compression garments were used (n = 137), 72 (53%)
were the more expensive custom‐made variety and 65 (47%) were
over‐the‐counter ready‐to‐wear products. Other therapies tried by
the participants by stage of lymphedema are shown in Table 2. As
expected, the number, complexity, and associated costs of therapies
used increased as the stage of lymphedema increased. Skin care, one
of the prescribed elements of complex lymphedema therapy (also
known as complete decongestive therapy), was not undertaken by
38% of participants. Of the 152 patients, 48% used compression
garments ranging from 14% for subclinical lymphedema to 100% for
severe lymphedema (χ2, P < .001). The use of laser therapy and
kinesiology tape also significantly varied by stage, but nearly all patients
had previously had lymphatic drainage massage, and very few had used
compression pumps or had undergone liposuction surgery.
Table 3 shows the reported out‐of‐pocket financial cost of lymph-
edema for all patients categorized by severity. The cost of compression
garments formed a large proportion of the financial costs (40.1%).
Visits to therapists, garment use, and costs increased as the severity
of lymphedema increased. Although limited by small numbers in the
TABLE 1 Basic demographics of patient group
Breast Cancer (%)
Breast Cancer and
Lymphedema (%) Pearson χ2,
P Valuen = 209 n = 152
Age at time of survey (y) <55 44.0 35.5 NS
≥55 56.0 64.5
Country of birth Australia 80.4 80.3 NS
United Kingdom 9.6 8.6
New Zealand 4.8 4.6
Other 5.2 6.5
Marital status Single, never married 9.1 6.6 NS




Primary carer No 65.6 57.9 NS
Yes, children 18.2 22.4
Yes, elderly parents 5.7 3.3
Yes, both 3.3 5.9
Yes, other 7.2 10.5
Years since treatment of breast cancer <5 74.6 55.9 <0.001
≥5 25.4 44.1
Years since diagnosis of lymphedema <5 — 65.1 —
≥5 34.9
Paid employment at diagnosis of breast cancer 77 63 .004
Total household income (A$) ≤45 000 20.6 15.1 NS
>45 000 to <100 000 29.2 31.6
≥100 000 32.1 34.9
Prefer not to say 18.2 18.4
Abbreviation: NS, not significant.
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severe group, the one exception was that the average number of visits
to a therapist was only 3.5 for severe lymphedema, less than for mild or
moderate lymphedema. This probably reflects the fact that severe
lymphedema is often fatty and fibrotic and is nonresponsive to conser-
vative therapies. The mean financial cost of lymphedema was A$ 977
(SD = A$111; range, A$0‐12 000). The median cost was A$525.
Further information on other financial impacts of breast
cancer with or without lymphedema is shown in Table 4. Of
patients with BC+LE, 80% indicated that their breast cancer diagnosis
had affected them financially compared with 67% in the BC alone
group (P < .020). For patients with lymphedema, over half (56%)
indicated that this specific additional diagnosis to their breast
TABLE 2 Treatments used by participants with lymphedema
Lymphedema Severity (%)
χ2, P Valuea
All Subclinical Mild Moderate Severe
N = 152 n = 14b n = 77 n = 55 n = 6b
Skin care 62 50 60 64 67 NS
Exercises 80 79 78 82 50 NS
Lymphatic drainage massage 93 100 92 85 100 NS
Compression garments 48 14 31 73 100 <.001
Laser therapy 35 14 22 56 50 <.001
Kinesiology taping 19 0 14 33 0 <.001
Pneumatic compression pumps 4 0 3 7 0 NS
Liposuction surgery 2 0 3 2 0 NS
Other 10 7 8 13 17 NS
Abbreviation: NS, not significant.
aP values used χ2 tests to assess the associations between the use of respective treatment (yes/no) and lymphedema severity groups (moderate/severe vs
subclinical/mild groups). The proportions shown above are only the “yes%” response.
bVery small sample size.
TABLE 3 Financial costs of lymphedema (A$)
Lymphedema Severity
P Valuea
All Subclinical Mild Moderate Severe
N = 152 n = 14b n = 77 n = 55 n = 6b
Visit to therapist
Average visits to lymphedema therapist per year 5.8 1.9 4.5 8.8 3.5 .001
Average cost of each visit (A$) 86 65 97 77 78 NS
Compression garment
Average number of garments ordered per year 2.2 0.5 2.0 2.6 4.3 .001
Average cost of garments per year (A$) 392 98 268 574 1000 <0.001
Estimate overall average expense in the last 12 months on lymphedema treatment
Mean (A$) 977 207 755 1433 1442 .003
SD (A$) 425 769 1944 1160 1369
Abbreviation: NS, not significant.
aP value used Kruskal‐Wallis test for the comparison of mean ranks across the 4 lymphedema severity subgroups.
bVery small sample size.
TABLE 4 Financial impact of breast cancer or lymphedema
Breast Cancer Impact (%) Lymphedema Impact (%)
BC Group BC+LE Group All Subclinical Mild Moderate Severe
N = 209 n = 152 n = 152 n = 14 n = 77 n = 55 n = 6
Condition has affected me financially 67 80 56 43 48 67 83
I have experienced financial distress 22 22 11 0 9 13 33
I have earned less income 39 34 15 7 0 24 17
I have had to cut down my holiday budget 21 19 13 0 12 16 50
I have had to cut down expenses in social activities (eg, going
out to movies or dinners)
24 24 16 14 5 22 33
I have chosen to see my lymphedema therapist in a public
setting
17 13 8 7 10 13 0
Abbreviations: BC, breast cancer without lymphedema; BC+LE, breast cancer with lymphedema.
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canceraffected them financially. In general, the worse the lymph-
edema, the greater the financial distress (Table 4). Specific comments
given about the financial impact of lymphedema are shown in Table 5
(Supporting Information).
Twenty‐five patients (16.4%) had an episode of cellulitis in the
past year. Twelve of 152 patients (7.9%) were admitted to hospital
owing to cellulitis for an average admission stay of 4.8 days (range,
1‐10 d). The total number of admission days was 57 for the 12 patients
admitted. The average number of days in hospital for cellulitis
associated with mild or moderate lymphedema (n = 3) was 4.0 versus
5.0 days for moderate/severe lymphedema (n = 9). The incidence of
cellulitis was 7 (7.7%) in 91 patients with subclinical or mild
lymphedema compared with 18 (29.5%) of 61 patients with moderate
to severe lymphedema (P < .001).
4 | DISCUSSION
Lymphedema is a feared complication of breast cancer and impacts
physical, functional, psychological, and social well‐being of patients
after treatment. However, existing scholarship is in the early stages
of development regarding many aspects of this condition. Our study
shows that, when compared with breast cancer survivors without
lymphedema, individuals living with lymphedema are worse off in
terms of out‐of‐pocket financial costs, with a substantial proportion
of these costs coming from compression garments. It is critical that
the issue of out‐of‐pocket expenses and other costs associated with
lymphedema are understood and evaluated to help shape policy for
health insurers and government.
The recommended best practice for care and treatment of
lymphedema and chronic edema includes the following: compression
(garments and/or bandaging); meticulous skin care; education; manual
lymphatic drainage; and exercise. These interventions are expensive in
terms of out‐of‐pocket costs and time off work or away from family. In
our study, 38% of patients were not undertaking any skin care, a
fundamental component of complete decongestive therapy found to
reduce cellulitis and admission costs from cellulitis.17
There have been some studies conducted in the United Kingdom
and the United States that estimate the health care costs of lymph-
edema, but none of these studies estimated the financial cost borne
by women.12,15,18 Out‐of‐pocket expenses typically relate to the costs
of seeing doctors or therapists, the purchase of over‐the‐counter or
more expensive custom‐made compression garments, the use of skin
creams and the prescription and purchase of antibiotics, and often
copayments after admission to hospital for cellulitis. Some idea of
the prevalence of these events was reported by Moffat18 in the United
Kingdom, where 27% of 823 patients with edema were admitted to
hospital for antibiotic treatment; 32% received some form of compres-
sion bandaging; and 29% had an infection in the past 12 months. The
mean length of stay was 12 days at a mean cost of £2300. Of note,
80% had taken time off work, and 8% had to give up work. This is com-
parable with our study, in which 25 patients (16.4%) had an episode of
cellulitis in the past year and 12 of 152 patients (7.9%) were admitted
to hospital because of cellulitis for an average admission stay of
5.6 days (range, 1‐10 d). Further, the incidence of cellulitis was 7.7%
in 91 patients with subclinical or mild lymphedema, compared with
29.5% of 61 patients with moderate to severe lymphedema (P < .001).
The National Hospital Cost Data Collection is the annual collection
of public hospital cost data in Australia. In 2014, the average cost per
admission for cellulitis was divided into less severe (80.6%) and more
severe cases (19.4%), with an average cost per admission of A$4102
and A$9605, respectively.19 In our series, this would have equated to
a total cost of $98 751 for the 12 patient admissions (3 less severe
and 9 more severe) and excludes 13 patients who were not admitted
but had to pay for medical visits and antibiotics and had to take time
off work.
A qualitative study from Canada reported aspects of abandonment
described by some participants because of the lack of financial support
available to cover the costs of treatment strategies. Compression
garments were expensive to buy, and a number of participants did
not have insurance. Those with insurance policies stated that there
was insufficient coverage for sleeve replacement costs. Participants
stated that the need for frequent cleaning caused compression
garments to lose elasticity and require regular replacement. Several
participants found the cost of compression pumps and massage
therapy prohibitive.20 In another study, issues influencing self‐care,
including the high cost of and insurance coverage for supplies, were
reported as slight to major problems by at least 20% of the
participants.21
In our study, when compression garments were used by 137
women, 53% were the more expensive custom‐made variety and
47% were over‐the‐counter ready‐to‐wear products. A common
theme among patients was the expense of garments and the lack of
financial reimbursement from the government or private health
insurance funds.
There have been limited studies on the impact of lymphedema on
financial costs borne by the patient. Gordon et al22 longitudinally
examined economic outcomes (costs and lost income) for 287
Australian patients with breast cancer up to 18 months after their
diagnosis. On average, patients incurred US$245 in out‐of‐pocket
financial costs, but compression sleeves for lymphedema were only
one component of these costs (ie, wigs, customized bras, etc, were also
included in this estimate). A previous US study demonstrated that can-
cer survivors were more likely to report a high annual out‐of‐pocket
burden than individuals without a history of cancer. This burden was
more common among cancer survivors compared with those without
a diagnosis of cancer, those without private insurance, and those not
working. Among cancer survivors, out‐of‐pocket burden was
associated with being unable to obtain necessary medical care and
delaying necessary medical care. Our experience is that many patients
still wear a compression sleeve even when it has significantly
diminished pressure to delay the expenditure for a replacement.23
A limitation of our study is that it used a cross‐sectional rather
than longitudinal survey design. As a result, we could not explore
whether these financial costs have increased over time. In addition,
as we asked participants to self‐report on the impact of lymphedema
over and above breast cancer, the study could be affected by recall
bias. However, a cross‐sectional design and the use of an online
survey allowed for a good sample size, and indicators of
lymphedema status were included, such as the number of symptoms
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and time since diagnosis. We also only included patients who had
seen a lymphedema therapist. Further, our study was not a formal
cost‐utility health economics study and may not be generalizable
to other health jurisdictions, particularly those with better support
for patients with lymphedema such as Scandinavia. Cheville et al24
argued that lymphedema is best estimated as a chronic disease by
utility values given its chronic nature and treatment that enhances
rather than extends patients' lives. To adequately review these
factors, we are planning a prospective study to further differentiate
the impact on finances from lymphedema versus the impact from
breast cancer.
These findings have implications for clinical practice, future
research, and policy‐making. Health professionals involved in the care
of patients with lymphedema must be aware that these women are at
risk of experiencing not only psychological distress and body image
disturbance25 but also potential finance‐related stress. Out‐of‐pocket
costs cause some patients who are under financial stress to delay
replacing their compression sleeves when they lose pressure and/or
delay seeing a lymphedema therapist, despite the benefit of treatment
in reducing the incidence of cellulitis.26,27 Our study shows that as
lymphedema becomes more advanced, episodes of cellulitis increase,
further compounding costs to the patient and the health system. The
lack of both appropriately trained and funded therapists and reim-
bursement for treatment is false economy in the long‐term for patients
whose lymphedema acts as a daily reminder of their previous breast
cancer treatment.
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